Zimmer Biomet (ZBH)
NYSEHealth CareMedical DevicesSnapshot 2026-07-08
$87.56-2.07%
Close 2026-07-08 · 1-day change
Reading ZBH? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ZBH free→NYSEHealth CareMedical DevicesSnapshot 2026-07-08
Reading ZBH? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ZBH free→QuarterlyIQ Insights · ZBH
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Entry into a Material Definitive Agreement. On June 26, 2026, Zimmer Biomet Holdings, Inc. (the “Company”) entered into a new five-year revolving credit agreement and a new 364-day revolving credit agreement, as described below. The Five-Year Revolving Credit Agreement, dated as of June 26, 2026, among the Company, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the “Five-Year Credit Agreement”), is a five-year unsecured revolving facility of $1.5 billion (th…
Termination of a Material Definitive Agreement. In connection with the entry into the Five-Year Credit Agreement and the 364-Day Credit Agreement, on June 26, 2026, the Five-Year Revolving Credit Agreement, dated as of June 27, 2025, among the Company, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the “2025 Five-Year Credit Agreement”), and the 364-Day Revolving Credit Agreement, dated as of June 27, 2025, among the Company, the lenders party thereto and JP…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The disclosure required by this Item is included in Item 1.01, which is incorporated herein by reference.
Regulation FD Disclosure. On May 12, 2026, Zimmer Biomet Holdings, Inc. (the “Company”) stated its intent to repurchase up to $1.0 billion of Company shares during fiscal year 2026 under the Company’s existing $1.5 billion share repurchase authorization, which had previously been approved by the Board of Directors of the Company in February 2026. This represents an increase from the Company’s previously-disclosed capital allocation assumptions for fiscal year 2026. The Company issued a press…
The excerpt does not provide sufficient information about a management change.
Chief Financial Officer and Executive Vice President – Finance, Operations and Supply Chain — Suketu Upadhyay: Mr. Upadhyay resigned to pursue a new professional opportunity.
Results of Operations and Financial Condition. On April 28, 2026, Zimmer Biomet Holdings, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1 and the information set forth therein is incorporated herein by reference and constitutes a part of this report. The information contained in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed…
Results of Operations and Financial Condition. On February 10, 2026, Zimmer Biomet Holdings, Inc. (the “Company”) issued a press release reporting its financial results for the quarter and year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 and the information set forth therein is incorporated herein by reference and constitutes a part of this report. The information contained in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deem…
named executive officer (former) — Mark Bezjak: Mr. Bezjak resigned to pursue another business opportunity.
Results of Operations and Financial Condition. On November 5, 2025, Zimmer Biomet Holdings, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 and the information set forth therein is incorporated herein by reference and constitutes a part of this report. The information contained in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be…
Other Events. As previously disclosed in the Current Report on Form 8-K filed by Zimmer Biomet Holdings, Inc. (the “Company”) on July 14, 2025 with the Securities and Exchange Commission, on July 11, 2025, the Company, entered into an Agreement and Plan of Merger with Monogram Technologies Inc., a Delaware corporation (“Monogram”), and Honey Badger Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”), as amended by that certain First Amendment to…
Other Events. On September 4, 2025, Zimmer Biomet Holdings, Inc. (the “ Company ”) issued two new series of senior unsecured debt securities denominated in Swiss francs, comprising CHF 210,000,000 aggregate principal amount of the Company’s 0.930% Bonds 2025 – 2030 (the “ Tranche A Bonds ”) and CHF 390,000,000 aggregate principal amount of the Company’s 1.560% Bonds 2025 – 2035 (the “ Tranche B Bonds ” and, together with the Tranche A Bonds, the “ Bonds ”). The Bonds were issued pursuant to a…
Results of Operations and Financial Condition. On August 7, 2025, Zimmer Biomet Holdings, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1 and the information set forth therein is incorporated herein by reference and constitutes a part of this report. The information contained in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed”…
Other Events. On July 11, 2025, the Company, entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Monogram Technologies Inc., a Delaware corporation (“Monogram”), and Honey Badger Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”). Subject to the terms and conditions of the Merger Agreement, Merger Sub will be merged with and into Monogram (the “Merger”), with Monogram continuing as the surviving corporation and a wholly-ow…
The 364-Day Revolving Credit Agreement, dated as of June 27, 2025, among the Company, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the “364-Day Credit Agreement”), is an unsecured revolving credit facility in the principal amount of $1.0 billion (the “364-Day Revolving Facility”). The 364-Day Credit Agreement will mature on June 26, 2026, and borrowings under the 364-Day Revolving Facility will be used for general corporate purposes. Borrowings under the 3…
Entry into a Material Definitive Agreement. On June 27, 2025, Zimmer Biomet Holdings, Inc. (the “Company”) entered into a new five-year revolving credit agreement and a new 364-day revolving credit agreement, as described below. The Five-Year Revolving Credit Agreement, dated as of June 27, 2025, among the Company, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the “Five-Year Credit Agreement”), is a five-year unsecured revolving facility of $1.5 billion (th…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The disclosure required by this Item is included in Item 1.01, which is incorporated herein by reference.
The filing describes amendments to the company's stock incentive plan, which is not a management change event.
Group President, Global Businesses and the Americas — Kevin Thornal: Kevin Thornal was appointed to a newly-created senior executive position.
Results of Operations and Financial Condition. On May 5, 2025, Zimmer Biomet Holdings, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended March 31, 2025. A copy of the press release is attached as Exhibit 99.1 and the information set forth therein is incorporated herein by reference and constitutes a part of this report. The information contained in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” w…
Other Events. As previously disclosed in the Current Report on Form 8-K filed by Zimmer Biomet Holdings, Inc. (the “Company”), on January 29, 2025 with the Securities and Exchange Commission, on January 28, 2025, Zimmer, Inc. (“Parent” or “Zimmer”), a Delaware corporation and wholly owned subsidiary of the Company, entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Paragon 28, Inc., a Delaware corporation (“Paragon 28”), Gazelle Merger Sub I, Inc., a Delaware corporati…
Chairman of the Board — Christopher Begley: Christopher Begley is retiring as Chairman of the Board due to the Company’s mandatory director retirement policy, with Ivan Tornos succeeding him.
Interest on the 2027 Notes accrues at a rate of 4.700% per annum, on the 2030 Notes at a rate of 5.050% per annum and on the 2035 Notes at a rate of 5.500% per annum, which interest, in each case, will be payable semi-annually in arrears on February 19 and August 19 of each year, commencing on August 19, 2025. Interest will be paid to the holders of record of the Notes at the close of business on the February 4 and August 4, respectively, immediately preceding the related interest payment dat…
Entry into a Material Definitive Agreement. On February 19, 2025, Zimmer Biomet Holdings, Inc. (the “Company”) completed its previously announced issuance of $600,000,000 aggregate principal amount of its 4.700% notes due 2027 (the “2027 Notes”), $550,000,000 aggregate principal amount of its 5.050% notes due 2030 (the “2030 Notes”) and $600,000,000 aggregate principal amount of its 5.500% notes due 2035 (the “2035 Notes” and, together with the 2027 Notes and the 2030 Notes, the “Notes”). The…
Entry into a Material Definitive Agreement. On February 11, 2025, Zimmer Biomet Holdings, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, Barclays Capital Inc., Citigroup Global Markets Inc., Morgan Stanley & Co. LLC and SMBC Nikko Securities America, Inc., as representatives of the underwriters named therein (collectively, the “Underwriters”), in connection with the public offering of $600 million aggregate principal am…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.